COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00205907
Recruitment Status : Terminated (Change in Formulation)
First Posted : September 21, 2005
Last Update Posted : March 6, 2008
Information provided by:
Aeris Therapeutics

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.

Condition or disease Intervention/treatment Phase
Pulmonary Emphysema Biological: BLVR Hydrogel Phase 1 Phase 2

Detailed Description:

Emphysema is a progressive, debilitating disease that affects nearly 3 million people in the United States or roughly one percent of the US population. The disease is characterized by destruction of lung tissue as a result of inflammation caused by exposure to noxious inhaled agents for extended periods. The most common cause of this condition is cigarette smoking, although genetic and occupational causes account for up to 10% of cases. Despite aggressive public health initiatives aimed at discouraging the use of cigarettes, smoking-related lung diseases remain a significant cause of disability and death in the United States. Currently there are 46 million smokers in the US. Due to the number of current and new smokers, emphysema is expected to remain a leading cause of morbidity and mortality in the United States for years to come.

Aeris has developed a novel bronchoscopic system for achieving the benefits of lung volume reduction without surgery. The Bronchoscopic Lung Volume Reduction (BLVR) Hydrogel System, a new investigational therapy for emphysema, is intended to reduce lung volume over a period of weeks by collapsing and promoting the remodeling of diseased areas of the lung. The resulting reduction in lung volume is intended to restore a more normal physiological relationship between lung and chest wall, improve breathing and exercise capacity and alleviate symptoms of chronic dyspnea. The current study will evaluate the safety and efficacy of this procedure in patients with advanced emphysema.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/Phase 2 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Emphysema
Study Start Date : January 2005
Actual Primary Completion Date : August 2006
Actual Study Completion Date : April 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Emphysema

Arm Intervention/treatment
Experimental: single
BLVR treatment
Biological: BLVR Hydrogel
10 mL BLVR Hydrogel

Primary Outcome Measures :
  1. Product-related life-threatening adverse events, permanently disabling complications and deaths [ Time Frame: 1 year post treatment ]
  2. FEV1 [ Time Frame: 12 weeks post treatment ]
  3. MRC Dyspnea Score [ Time Frame: 12 weeks post treatment ]
  4. Six-Minute Walk Test [ Time Frame: 12 weeks post treatment ]
  5. Health-Related Quality of Life [ Time Frame: 12 weeks post treatment ]

Secondary Outcome Measures :
  1. Lung function tests [ Time Frame: 12 weeks post treatment ]
  2. Lung volume measures [ Time Frame: 12 weeks post treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria include:

  • Clinical diagnosis of advanced heterogeneous emphysema
  • Age > 18 years at the time of initial presentation
  • Clinically significant dyspnea (MRC Dyspnea >/= 2)
  • Failure of standard medical therapy to provide relief of symptoms
  • BUN, creatinine, ALT, AST, alkaline phosphatase, WBC, hematocrit, platelet count, PT and PTT within normal limits
  • Pulmonary function tests

Exclusion Criteria:

  • Alpha-1 protease inhibitor deficiency verified by a serum level of < 80 mg% or knowledge of PI*ZZ genotype
  • Body mass index < 15 kg/m2 or > 35 kg/m2
  • Clinically significant asthma (reversible airway obstruction), chronic bronchitis or bronchiectasis
  • Tobacco use within 16 weeks of the initial clinic visit
  • Allergy to fish or pork products or sensitivity to tetracycline
  • FEV1 <20% with DLCO <20% or homogeneous disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00205907

Layout table for location information
Chaim Sheba (Tel Hashomer) Medical Center
Ramat Gan, Israel, 52621
Sponsors and Collaborators
Aeris Therapeutics
Layout table for investigator information
Principal Investigator: Issahar Ben-Dov, MD The Chaim Sheba Medical Center
Additional Information:
Layout table for additonal information
Responsible Party: Edward P Ingenito, MD, PhD, Medical Director & CSO, Aeris Therapeutics Inc Identifier: NCT00205907    
Other Study ID Numbers: C04-003
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: March 6, 2008
Last Verified: February 2008
Keywords provided by Aeris Therapeutics:
chronic obstructive pulmonary disease
pulmonary emphysema
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases